The Division of Drug Information (DDI) is CDER's focal point for public
inquiries. We serve the public by providing information on human drug
products and drug product regulation by FDA.



FDA is approving a new indication for the cholesterol lowering
medication CRESTOR (rosuvastatin). CRESTOR will now be indicated for
the primary prevention of cardiovascular disease to reduce the risk of
stroke, heart attack, and the risk of arterial revascularization
procedures (including coronary artery bypass graft, or bypass grafting
of a peripheral artery or carotid artery, or angioplasty or stent
placement) in individuals who have no clinically evident heart disease
but are at an increased risk of heart disease due to the combined
effect of the following risk factors:

- Age (> 50 years in men; > 60 years in women), and
- An elevated high-sensitivity C-reactive protein level (> 2 mg/L), and
- Presence of at least one additional cardiovascular risk factor (e.g.,
high blood pressure, low HDL-C, smoking, or a family history of
premature heart disease).
CRESTOR is in a class of drugs called "statins." Statins work by
stopping an enzyme called HMG-CoA reductase from making cholesterol.
High cholesterol is a known risk factor for heart attacks and strokes.

For more information, please visit: Crestor

This is an automated message delivery system. Replying to this message
will not reach DDI staff. If you have comments or questions, please
contact us at: 1-888-INFO FDA (1-888-463-6332) or (301) 796-3400 from
8:00 am - 4:30 pm Monday - Friday. You can also email us at
druginfo@fda.hhs.gov.

- For additional drug information, please visit the DDI Web page.
- For up-to-date drug information, follow the FDA’s Division of Drug
Information on Twitter: FDA_Drug_Info
- This service is provided to you at no charge by the U.S. Food & Drug
Administration (FDA).


Manage your FDA Subscriptions:

- Update your preferences or unsubscribe
- Questions about this service? support@govdelivery.com
- Other inquiries? webmail@oc.fda.gov


GovDelivery, Inc. sending on behalf of U.S. Food & Drug Administration
(FDA) · 5600 Fishers Lane · Rockville MD 20857 · 800-439-1420